Olema Pharmaceuticals (OLMA)
(Delayed Data from NSDQ)
$11.85 USD
-0.89 (-6.99%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $11.86 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.85 USD
-0.89 (-6.99%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $11.86 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Zacks News
Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why
by Zacks Equity Research
Olema Pharmaceuticals (OLMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
by Zacks Equity Research
Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.
Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Olema Pharmaceuticals, Inc. (OLMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 76.5% in Olema Pharmaceuticals, Inc. (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep going
by Zacks Equity Research
Olema Pharmaceuticals, Inc. (OLMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Olema Pharmaceuticals, Inc. (OLMA) Have the Potential to Rally 80.29% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Olema Pharmaceuticals, Inc. (OLMA) points to an 80.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's What Could Help Olema Pharmaceuticals, Inc. (OLMA) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Olema Pharmaceuticals, Inc. (OLMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What Makes Olema Pharmaceuticals, Inc. (OLMA) a New Buy Stock
by Zacks Equity Research
Olema Pharmaceuticals, Inc. (OLMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 91.97% Upside in Olema Pharmaceuticals, Inc. (OLMA): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 92% in Olema Pharmaceuticals, Inc. (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Olema Pharmaceuticals, Inc. (OLMA) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Olema Pharmaceuticals, Inc. (OLMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug
by Zacks Equity Research
The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.